Veliparib

Generic Name: Veliparib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₁₆N_₄O

CAS Number: 912444-00-9

Unique Ingredient Identifier: 01O4K0631N

Indication: 与化疗药物紫杉醇和卡铂联合用于治疗乳腺癌。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2

Completed

Conditions: Recurrent Prostate Carcinoma
Castration-Resistant Prostate Carcinoma
Stage IV Prostate Cancer AJCC v7

Interventions: Drug: Abiraterone Acetate
Other: Laboratory Biomarker Analysis
Drug: Prednisone
Drug: Veliparib

First Posted Date: 2012-04-12

Last Posted Date: 2020-11-12

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 159

Registration Number: NCT01576172

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸
City of Hope South Pasadena, South Pasadena, California, United States
🇺🇸
NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States

and more 11 locations

A Clinical Study Conducted in Multiple Centers Comparing Veliparib in Combination With Carboplatin and Paclitaxel Versus a Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Non-Small -Cell Lung Cancer

Interventions: Drug: Carboplatin
Drug: Veliparib
Drug: placebo
Drug: paclitaxel

First Posted Date: 2012-03-22

Last Posted Date: 2015-10-21

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 160

Registration Number: NCT01560104

Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2

Completed

Conditions: BRCA2 Mutation Carrier
Recurrent Fallopian Tube Carcinoma
Ovarian Epithelial Tumor
Recurrent Ovarian Carcinoma
BRCA1 Mutation Carrier
Recurrent Primary Peritoneal Carcinoma

Interventions: Other: Laboratory Biomarker Analysis
Drug: Veliparib

First Posted Date: 2012-02-29

Last Posted Date: 2019-07-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 52

Registration Number: NCT01540565

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸
The Hospital of Central Connecticut, New Britain, Connecticut, United States

and more 150 locations

Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas

Phase 1

Completed

Conditions: Fibrillary Astrocytoma
Untreated Childhood Anaplastic Astrocytoma
Anaplastic Astrocytoma
Giant Cell Glioblastoma
Glioblastoma
Gliosarcoma
Untreated Childhood Fibrillary Astrocytoma
Untreated Childhood Gliosarcoma
Childhood Mixed Glioma
Untreated Childhood Brain Stem Glioma

Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy
Radiation: Intensity-Modulated Radiation Therapy
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Temozolomide
Drug: Veliparib

First Posted Date: 2012-01-23

Last Posted Date: 2019-08-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 66

Registration Number: NCT01514201

Locations: 🇺🇸
Lurie Children's Hospital-Chicago, Chicago, Illinois, United States
🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

and more 9 locations

Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer

Phase 2

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Placebo
Drug: Veliparib
Drug: Carboplatin
Drug: Temozolomide
Drug: Paclitaxel

First Posted Date: 2012-01-10

Last Posted Date: 2021-10-25

Lead Sponsor: AbbVie

Target Recruit Count: 294

Registration Number: NCT01506609

Locations: 🇨🇦
Sunnybrook Health Sciences Ctr /ID# 77373, Toronto, Ontario, Canada
🇺🇸
The Angeles Clinic and Researc /ID# 60743, Los Angeles, California, United States
🇺🇸
University of Pennsylvania /ID# 60753, Philadelphia, Pennsylvania, United States

and more 117 locations

Veliparib With Radiation Therapy in Patients With Inflammatory or Loco-regionally Recurrent Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: Veliparib
Radiation: Standard radiation treatment

First Posted Date: 2011-11-22

Last Posted Date: 2017-12-15

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 33

Registration Number: NCT01477489

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 2 locations

Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA Mutation

Phase 1

Completed

Conditions: Recurrent, Epithelial Ovarian Cancer

Interventions: Drug: Veliparib

First Posted Date: 2011-11-16

Last Posted Date: 2016-11-16

Lead Sponsor: Vejle Hospital

Target Recruit Count: 49

Registration Number: NCT01472783

Locations: 🇩🇰
Department of Oncology, Vejle Hospital, Vejle, Denmark

Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Phase 1

Completed

Conditions: Ovarian Clear Cell Cystadenocarcinoma
Recurrent Fallopian Tube Carcinoma
Recurrent Ovarian Carcinoma
Ovarian Endometrioid Adenocarcinoma
Ovarian Serous Cystadenocarcinoma
Ovarian Seromucinous Carcinoma
Recurrent Primary Peritoneal Carcinoma
Undifferentiated Ovarian Carcinoma

Interventions: Biological: Bevacizumab
Drug: Carboplatin
Other: Laboratory Biomarker Analysis
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
Drug: Veliparib

First Posted Date: 2011-10-25

Last Posted Date: 2019-07-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 41

Registration Number: NCT01459380

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸
Augusta University Medical Center, Augusta, Georgia, United States
🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States

and more 10 locations

Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Advanced Malignant Solid Neoplasm

Interventions: Drug: Dinaciclib
Drug: Veliparib

First Posted Date: 2011-09-14

Last Posted Date: 2024-08-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 121

Registration Number: NCT01434316

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Phase 1

Active, not recruiting

Conditions: Lung Adenocarcinoma, Mixed Subtype
Minimally Invasive Lung Adenocarcinoma
Lung Adenocarcinoma
Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Lung Large Cell Carcinoma
Lung Squamous Cell Carcinoma
Stage III Lung Non-Small Cell Cancer AJCC v7
Stage IIIB Lung Non-Small Cell Cancer AJCC v7

Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy
Drug: Carboplatin
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Drug: Veliparib
Other: Placebo Administration

First Posted Date: 2011-07-01

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 53

Registration Number: NCT01386385

Locations: 🇺🇸
Alaska Women's Cancer Care, Anchorage, Alaska, United States
🇺🇸
Anchorage Oncology Centre, Anchorage, Alaska, United States
🇺🇸
Katmai Oncology Group, Anchorage, Alaska, United States

and more 231 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy